Journals / Üroonkoloji Bülteni / 2021 / Cilt: 20 - Sayı: 4

Intravesical Bacillus Calmette-Guérin Treatment During The Coronavirus Disease-2019 Pandemic: A Review of Current Recommendations

Pages
206–209
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, it is recommended to at least complete induction therapy in high-risk NMIBC as the risk of progression and recurrence is high.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Many outpatient procedures were restricted to reduce the likelihood of transmission during the coronavirus disease-2019 (COVID-19) pandemic.
📊
Key Findings & Data:Materials and Methods: A comprehensive literature review was performed between January 2020 and December 2020 within the PubMed and Google Scholar databases.
💡
Conclusion & Impact:However, it is recommended to at least complete induction therapy in high-risk NMIBC as the risk of progression and recurrence is high.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Many outpatient procedures were restricted to reduce the likelihood of transmission during the coronavirus disease-2019 (COVID-19) pandemic. The most effective treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) is the intravesical Bacillus Calmette-Guérin (BCG) therapy, consisting of induction and maintenance, which requires repeated hospital visits. Therefore, treatment protocol adaptation to the pandemic is important. Materials and Methods: A comprehensive literature review was performed between January 2020 and December 2020 within the PubMed and Google Scholar databases. Results: Recommendations and updates of two international associations, two national associations, and five intravesical BCG application studies were discussed. During the pandemic, intravesical BCG treatment was delayed for patients with NMIBC in the intermediate-risk group. The general view for patients in the high-risk group is to complete induction therapy, if possible. Recommendations for maintenance treatment vary. With this treatment, planning should be done in less than one year. The existence of suspected or approved COVID-19 disease delayed the BCG treatment for 3 weeks. Conclusion: Consensus was not found on how intravesical BCG treatment should be applied during the pandemic. However, it is recommended to at least complete induction therapy in high-risk NMIBC as the risk of progression and recurrence is high. BCG instillations can be delayed for at least 3 weeks in patients with confirmed COVID-19 disease.

🔖

Cite This Article

Ok, F. (2022). Intravesical Bacillus Calmette-Guérin Treatment During The Coronavirus Disease-2019 Pandemic: A Review of Current Recommendations. Üroonkoloji Bülteni, Cilt: 20 - Sayı: 4, 206–209. https://ajindex.com/articles/645707

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ok F, Erdogan O, Durmus E, et al. Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients. J Med Virol 2021;93:786-793
  2. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970
  3. Lenfant L, Seisen T, Loriot Y, Rouprêt M. Adjustments in the use of intravesical instillations of bacillus calmette-guérin for high-risk nonmuscle- invasive bladder cancer during the COVID-19 pandemic. Eur Urol 2020;78:1-3
  4. Ribal MJ, Cornford P, Briganti A, et al; EAU Section Offices and the EAU Guidelines Panels. European Association of Urology Guidelines Office rapid reaction group: an organisation-wide collaborative effort to adapt the european association of urology guidelines recommendations to the coronavirus disease 2019 era. Eur Urol 2020;78:21-28
  5. American Urological Association. BCG Shortage Info. Erişim tarihi Avaialble from:
  6. British Association of Urological Surgeons. About coronavirus & COVID-19. Last Accesed Date: 10.04.2020. Available from: www. baus.org.uk/about/coronavirus_covid-19.aspx
  7. Çelik S, Tınay İ, Narter F, et al. Management of patients with urological cancers in Turkey during the COVID-19 pandemic: Recommendations of Uro-oncology Association. Bull Urooncol 2020;19:100-103
  8. Hegarty PK, Kamat AM, Zafirakis H, Dinardo A. BCG vaccination may be protective against Covid-19. 2020 preprint. doi: 10.13140/ RG.2.2.35948.10880 9. Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cellmediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009;83:3528-3539
  9. Kamat AM, Bellmunt J, Galsky MD, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 2017;5:68
  10. Wallis CJD, Novara G, Marandino L, et al. Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management During the COVID-19 pandemic. Eur Urol 2020;78:29-42
  11. Katz EG, Stensland KD, Mandeville JA, et al. Triaging Office Based Urology Procedures during the COVID-19 Pandemic. J Urol 2020;204:9-10
  12. Ficarra V, Novara G, Abrate A, et al. Research Urology Network (RUN). Urology practice during the COVID-